On this page
MTR
5-methyltetrahydrofolate-homocysteine methyltransferase
The MTR gene encodes methionine synthase, an enzyme vital for amino acid metabolism, particularly in converting homocysteine to methionine. The MTR gene provides instructions for creating methionine synthase, an enzyme that plays a crucial role in the body's processing of amino acids.
MTR is located on the long (q) arm of chromosome 1, at band 1q43. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 1 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The MTR gene, also known as 5-methyltetrahydrofolate-homocysteine methyltransferase, is responsible for producing the enzyme methionine synthase. This enzyme is a key component in a metabolic pathway that converts homocysteine into methionine, an essential amino acid. Proper functioning of methionine synthase is critical for cellular metabolism and overall health.
What the gene does
Methionine synthase, encoded by the MTR gene, facilitates a vital chemical reaction in amino acid metabolism. Specifically, it converts the amino acid homocysteine into methionine. This enzymatic process is dependent on methylcobalamin, a form of vitamin B12, and is also supported by another enzyme called methionine synthase reductase. Methionine is subsequently used by the body for protein synthesis and the production of other important biological compounds, while the conversion helps to regulate homocysteine levels, which can be detrimental if too high.
Video: Genetics 101
Chromosome location
The MTR gene is situated on the long arm of chromosome 1, at position 1q43. This genomic location indicates its specific address within the human genome, providing a reference point for understanding its genetic context.
Protein structure
The methionine synthase protein consists of 1265 amino acids and features several distinct functional domains. These include the Hcy-binding domain, spanning amino acids 19-338, and the Pterin-binding domain, located from amino acids 371-632. Additionally, there are two B12-binding domains: one at the N-terminal end (amino acids 662-759) and another (amino acids 772-907). The protein also contains an AdoMet activation domain, found at amino acids 923-1265, which is essential for its catalytic activity.
Key variants
Genetic variations within the MTR gene can impact the structure and function of the methionine synthase enzyme. These changes may range from single amino acid substitutions to alterations that lead to a truncated, non-functional protein. Such variants can disrupt the enzyme's ability to process homocysteine effectively, leading to metabolic imbalances.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1200dup | p.Val401fs | Pathogenic/Likely pathogenic | ★★☆☆ | Methylcobalamin deficiency type cblG |
c.1941dup | p.Arg648fs | Pathogenic | ★★☆☆ | Methylcobalamin deficiency type cblG |
c.1992_1993insATCA | p.Glu665fs | Pathogenic | ★★☆☆ | Methylcobalamin deficiency type cblG |
c.2100dup | p.Tyr701fs | Pathogenic/Likely pathogenic | ★★☆☆ | Methylcobalamin deficiency type cblG |
c.2101del | p.Tyr701fs | Pathogenic | ★★☆☆ | Neural tube defects, folate-sensitive |
c.2404C>T | p.Arg802Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Methylcobalamin deficiency type cblG |
c.2474-1G>C | - | Pathogenic | ★★☆☆ | Methylcobalamin deficiency type cblG |
c.2799_2803del | p.Ala935fs | Pathogenic | ★★☆☆ | Methylcobalamin deficiency type cblG |
c.3439C>T | p.Arg1147Ter | Pathogenic | ★★☆☆ | Methylcobalamin deficiency type cblG |
c.609+1088G>A | - | Pathogenic | ★★☆☆ | Methylcobalamin deficiency type cblG |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in the MTR gene are associated with inherited metabolic disorders, including homocystinuria. This condition arises from the impaired function of methionine synthase, leading to an accumulation of homocysteine in the body. Furthermore, specific MTR gene variants have been linked to potential health concerns during prenatal development.
No condition pages are linked to this gene yet. This does not mean it has no associated conditions.
Inheritance pattern
Conditions caused by pathogenic MTR variants typically follow autosomal recessive inheritance.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
UK clinical status
The MTR gene is currently included in several UK NHS national genomic testing panels. It is listed on panels for Cytopenias and congenital anaemias, Intellectual disability, and Undiagnosed metabolic disorders. It is also recognised on the DDG2P (Deciphering Developmental Disorders) and Rare anaemia (R92) panels, as well as the Likely inborn error of metabolism (R98) panel.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What is the main function of the MTR gene?
The MTR gene provides instructions for making the methionine synthase enzyme. This enzyme is crucial for converting homocysteine into methionine, an essential amino acid used for building proteins and other vital compounds.
What is homocystinuria, and how is it related to the MTR gene?
Homocystinuria is an inherited metabolic disorder characterised by high levels of homocysteine in the body. It is often caused by pathogenic variants in the MTR gene, which lead to a dysfunctional methionine synthase enzyme, preventing the proper conversion of homocysteine.
Is the MTR gene involved in vitamin B12 metabolism?
Yes, the methionine synthase enzyme encoded by the MTR gene requires methylcobalamin, a form of vitamin B12, to function correctly. This makes the gene's activity directly dependent on adequate vitamin B12.
References
- Guéant-Rodriguez RM, Rendeli C, Namour B. Transcobalamin and methionine synthase reductase mutated polymorphisms aggravate the risk of neural tube defects in humans. Neuroscience letters. 2003. PMID: 12812837
- Bosco P, Guéant-Rodriguez RM, Anello G. Methionine synthase (MTR) 2756 (A --> G) polymorphism, double heterozygosity methionine synthase 2756 AG/methionine synthase reductase (MTRR) 66 AG, and elevated homocysteinemia are three risk factors for having a child with Down syndrome. American journal of medical genetics. Part A. 2003. PMID: 12923861
- Carmel R, Green R, Rosenblatt DS. Update on cobalamin, folate, and homocysteine. Hematology. American Society of Hematology. Education Program. 2003. PMID: 14633777
- Watkins D, Ru M, Hwang HY. Hyperhomocysteinemia due to methionine synthase deficiency, cblG: structure of the MTR gene, genotype diversity, and recognition of a common mutation, P1173L. American journal of human genetics. 2002. PMID: 12068375
- Doolin MT, Barbaux S, McDonnell M. Maternal genetic effects, exerted by genes involved in homocysteine remethylation, influence the risk of spina bifida. American journal of human genetics. 2002. PMID: 12375236